Navigation Links
NW Bio To Present At Biotech Showcase 2014
Date:1/9/2014

BETHESDA, Md., Jan. 9, 2014 /PRNewswire/ -- Northwest Biotherapeutics, Inc. (NASDAQ: NWBO) ("NW Bio"), a biotechnology company developing non-toxic DCVax® personalized immune therapies for cancer, announced today that Linda Powers, CEO, will present at the Biotech Showcase™ 2014 Conference that is being held in San Francisco from January 13-15, 2014.

(Logo: http://photos.prnewswire.com/prnh/20110329/SF73084LOGO)

NW Bio's presentation will take place on Monday, January 13, at 4:00 p.m. PST in the Mission II Room at the Parc55 Hotel Wyndham, 55 Cyril Magnin St, Union Square.  There will be a live audio webcast of the presentation available at http://nwbio.com/webcasts/.  During her presentation, Ms. Powers will provide an overview of the Company's cancer vaccine platform technology, product pipeline and  clinical programs with DCVax-L and DCVax-Direct.

If you are interested in meeting with NW Bio's management during the conference, please contact Lisa Sher of MBS Value Partners at Lisa.Sher@mbsvalue.com.

About Northwest Biotherapeutics

Northwest Biotherapeutics is developing cancer vaccines designed to treat a broad range of solid tumor cancers more effectively than current treatments, and without the side effects of chemotherapy drugs.  NW Bio's proprietary manufacturing technology enables the Company to produce its personalized vaccine in an efficient, cost-effective manner.  The Company has a broad platform technology for DCVax dendritic cell-based vaccines.  The Company's lead product, DCVax-L, is currently in a 312-patient Phase III trial in the U.S. and Europe for patients with newly diagnosed Glioblastoma multiforme (GBM), the most aggressive and lethal brain cancer.  The Company's second product, DCVax-Direct, is currently in a 60-patient Phase I/II trial for direct injection into all types of inoperable solid tumor cancers.  The Company has also conducted a small Phase I/II trial with DCVax for metastatic ovarian cancer together with the University of Pennsylvania.  The Company previously received clearance from the FDA for a 612-patient Phase III trial with its third product, DCVax-Prostate, for late stage prostate cancer.

Disclaimer

Statements made in this news release that are not historical facts, including statements concerning future treatment of patients using DCVax and future clinical trials, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  Words such as "expect," "believe," "intend," "plan," "continue," "may," "will," "anticipate," and similar expressions are intended to identify forward-looking statements.  Actual results may differ materially from those projected in any forward-looking statement.  Specifically, there are a number of important factors that could cause actual results to differ materially from those anticipated, such as the Company's ability to raise additional capital, risks related to the Company's ability to enroll patient s in its clinical trials and complete the trials on a timely basis, the uncertainty of the clinical trials process, uncertainties about the timely performance of third parties, and whether the Company's products will demonstrate safety and efficacy.  Additional information on these and other factors, including Risk Factors, which could affect the Company's results, is included in its Securities and Exchange Commission ("SEC") filings.  Finally, there may be other factors not mentioned above or included in the Company's SEC filings that may cause actual results to differ materially from those projected in any forward-looking statement. You should not place undue reliance on any forward-looking statements.  The Company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by securities laws.


'/>"/>
SOURCE Northwest Biotherapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Report Presents a Framework for Successful New Oncology Product Launches in the Pharmaceutical Sector
2. Latest Findings in Breastfeeding Science Presented at Medelas 7th International Breastfeeding and Lactation Symposium
3. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
4. Enox Biopharma, Inc. To Present Today At IN3 Medical Device 360 Conference In London
5. Foundation for Managed Care Pharmacy (FMCP) Presents Awards for 2012 National P&T Competition and Best Posters
6. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2012 Financial Results
7. Interim results of VITOBA™ (VImpaT® added to One Baseline AED) Study Presented at the 64th Annual Meeting of the American Academy of Neurology
8. Hospira to Present at the Bank of America Merrill Lynch 2012 Health Care Conference
9. Ultra Clean to Present at the Jefferies 2012 Global Technology, Media & Telcom Conference
10. Anlit to Present New Dietary Supplements for Children at Vitafoods Europe 2012
11. Avanir Pharmaceuticals To Present at Three Conferences In May
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/17/2017)... , Feb. 17, 2017  Perrigo Company plc (NYSE, TASE: PRGO) ... Food and Drug Administration for hydrocodone bitartrate and homatropine methylbromide ... Hydrocodone bitartrate and homatropine methylbromide oral solution (syrup), ... symptomatic relief of cough in adults and children 6 years ... ending January 2017 were approximately $16 million.   ...
(Date:2/17/2017)... , Feb. 17, 2017  In partnership with ... for Good Health , The Jack Brewer Foundation ... with millions of dollars, worth of medicine to ... . IHI is a non-profit dedicated to treating chronic ... extremely active in Haiti and ...
(Date:2/17/2017)... NEW YORK , February 17, 2017 ... Composite and the S&P 500 edged lower at the ... its bullish streak above the 20,000 benchmark. Moreover, five ... bearish territories. Taking into consideration yesterday,s market sentiment, Stock-Callers.com ... morning: Smith & Nephew PLC (NYSE: SNN ...
Breaking Medicine Technology:
(Date:2/18/2017)... ... ... Butler Mobility invited Ken Matthews to visit its manufacturing facility and showroom to ... with the safety and reliability of the Stannah Stairlift as well as with the ... by Ken Matthews can be heard on News Radio WHP 580 weekdays from 3:00 ...
(Date:2/18/2017)... ... February 18, 2017 , ... ProParagraph Fashion ... Film Studios ’ ProParagraph Fashion Volume 2 for all multi-line FCPX project needs. ... Users can pick and choose from hand-crafted trend-setting designs with smooth animations that ...
(Date:2/17/2017)... ... February 17, 2017 , ... While EHR data has revolutionized ... an innovative workstation designed to reduce nursing fatigue while enhancing productivity. Based on ... offers a lightweight, highly mobile, multi-functional alternative to the limitations of handheld computing. ...
(Date:2/17/2017)... ... February 17, 2017 , ... For the first ... solution to the exhibit floor for the 2017 HIMSS Conference & Exhibition ... Feb. 19–23, 2017, more than 40,000 healthcare industry professionals are expected at the ...
(Date:2/17/2017)... ... February 17, 2017 , ... Corrective Action ... Letter, **An FDAnews Webinar**, Feb. 23, 2017 — 1:30 p.m. – 3:00 p.m. ... action (CA) and preventive action (PA)? , The methods share techniques and tools ...
Breaking Medicine News(10 mins):